GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Autolus Therapeutics PLC (FRA:6A3A) » Definitions » Policy Acquisition Expense

Autolus Therapeutics (FRA:6A3A) Policy Acquisition Expense


View and export this data going back to 2018. Start your Free Trial

What is Autolus Therapeutics Policy Acquisition Expense?

Policy Acquisition Expense only applies to insurance companies.


Autolus Therapeutics (FRA:6A3A) Business Description

Traded in Other Exchanges
Address
191 Wood Lane, The MediaWorks, London, GBR, W12 7FP
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.